Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis

NCT01663623 is registered in ClinicalTrials.gov with Human Genome Sciences Inc., a GSK Company as lead sponsor.

NCT NCT01663623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01663623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Phase
Phase 3
Overall status
Completed
Start date
March 20, 2013
Completion date
February 6, 2017
Enrollment
106 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

vasculitis